1122PInterim analysis of a single arm phase II study of adjuvant nivolumab after salvage resection in head and neck squamous cell carcinoma patients previously treated with definitive therapy

ConclusionsAdjuvant nivolumab after salvage surgery in HNSCC patients is safe however, increased enrollment is required to establish efficacy.Clinical trial identificationNCT03355560.Legal entity responsible for the studyTrisha Wise-Draper.FundingBMS.DisclosureT. Wise-Draper: Research grant / Funding (self): BMS; Research grant / Funding (self): AstraZeneca; Research grant / Funding (self): Merck; Research grant / Funding (institution): Tesaro. All other authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research